Does the Choice of Treatment of Diabetes Mellitus Change Natural Course of Alzheimer Disease? | OMICS International| Abstract
ISSN: 2161-0460

Journal of Alzheimers Disease & Parkinsonism
Open Access

Like us on:

Our Group organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Open Access Journals gaining more Readers and Citations
700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers

This Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)
  • Review Article   
  • J Alzheimers Dis Parkinsonism 2018, Vol 8(1): 415
  • DOI: 10.4172/2161-0460.1000415

Does the Choice of Treatment of Diabetes Mellitus Change Natural Course of Alzheimer Disease?

Emina Karahmet1, Besim Prnjavorac2,3,4,5*, Asja Sejranić6, Esma Karahmet7, Aida Mujaković5, Katarina Krajina8, Amela Hasanović-Gogić9 and Nina Delić9
1Berlin-Chemie Menarini Representative Office BiH, , Sarajevo, USA
2General Hospital Tešanj, Bosnia and Herzegovina (BiH), , USA
3School of Medicine, University of Zenica, , BiH, USA
4Faculty of Pharmacy, International University Sarajevo, BiH, USA
5School of Medicine, , SSST Sarajevo, BiH, USA
6JZU Gradska apoteka Tuzla, BiH, , USA
7Medis Representative Office BiH, , Sarajevo, USA
8University of Pittsburgh, PA, USA
9ApotekaIbnSina-Stupina , Tuzla, , Bosnia
*Corresponding Author : Besim Prnjavorac, Faculty of Pharmacy, International University Sarajevo, BiH, USA, Tel: +387 32 650 662, Email: [email protected]

Received Date: Aug 17, 2017 / Accepted Date: Jan 08, 2018 / Published Date: Jan 15, 2018


Alzheimer disease (AD) is common worldwide and almost every case has comorbidities. One of the most common comorbidities of AD is Diabetes mellitus (DM), with or without metabolic syndrome. Both diseases effect nerve tissue and successful treatment would improve the status of the patient. In patients with Alzheimer disease treatment of DM, the treatment could be harmful to the AD, because of that high insulin intake. This may lead to progression of AD. Insulin is considered the best treatment for DM, but insulin therapy could increase comorbidity with AD. No specific therapy for AD is known up to date, so because of that DM is one of the most important risk for AD, concomitant therapy for DM should be planned very carefully. All options of DM therapy should be considered, and different mechanisms of anti-diabetic drugs are preferable. Treatment of AD is more complex metabolic syndrome is present. Any inflammation causes local tissue damage, including brain tissue during AD. Release of interleukins, primarily TNF-α, IL-6, IL-1β in the presence of adipokine leptin, maintains chronic inflammatory status in local brain tissue. Thus, low doses of immunosuppressant therapy should be considered for treatment of AD in future. To delay apoptosis of nerve tissue cells, brain and nerve tissue defend against free oxygen radicals and improve metabolic status.

Keywords: Alzheimer disease; Diabetes mellitus; Treatment; Insulin

Citation: Karahmet E, Prnjavorac B, Sejranić A, Karahmet E, Mujaković A, et al. (2018) Does the Choice of Treatment of Diabetes Mellitus Change Natural Course of Alzheimer Disease? J Alzheimers Dis Parkinsonism 8: 415. Doi: 10.4172/2161-0460.1000415

Copyright: ©2018 Karahmet E, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.